4,152 results match your criteria Imaging in Prostate Carcinoma

Large-cell neuroendocrine tumor of the prostate: a case report and review of the literature.

J Med Case Rep 2021 May 7;15(1):254. Epub 2021 May 7.

Urology Department, René Dubos Hospital, Pontoise, France.

Background: Primitive neuroendocrine prostate neoplasms are rarely reported. This entity comprises carcinoïd tumors and poorly differentiated neuroendocrine tumors, mainly those of the small-cell type. Large-cell-type primitive tumors are exceptional, and only nine cases are reported in the literature. Read More

View Article and Full-Text PDF

Real-world Israeli single institution experience with PET-PSMA for staging of patients with clinically staged localized prostate carcinoma.

Cancer Rep (Hoboken) 2021 May 2:e1386. Epub 2021 May 2.

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Background: A recent prospective trial, the proPSMA study, showed superior specificity and sensitivity of Positron emission tomography (PET) - Prostate-specific membrane antigen (PSMA) imaging compared standard Computerized tomography (CT) and bone scan for staging of recently diagnosed high-risk local prostate carcinoma for curative intent treatment.

Aim: To share our experience with false-positive PET PSMA scans in newly diagnosed intermediate-risk prostate cancer.

Methods And Results: Here, we report a series of eight patients who underwent systemic staging using PET-PSMA with false-positive results who were ultimately treated with definitive radiation or surgery. Read More

View Article and Full-Text PDF

Standardization of the [Ga]Ga-PSMA-11 Radiolabeling Protocol in an Automatic Synthesis Module: Assessments for PET Imaging of Prostate Cancer.

Pharmaceuticals (Basel) 2021 Apr 21;14(5). Epub 2021 Apr 21.

Hospital Israelita Albert Einstein, Sao Paulo 05652-900, Brazil.

Prostate-specific membrane antigen (PSMA) is a glycoprotein present in the prostate, that is overexpressed in prostate cancer (PCa). Recently, PSMA-directed radiopharmaceuticals have been developed, allowing the pinpointing of tumors with the Positron Emission Tomography (PET) or Single Photon Emission Computed Tomography (SPECT) imaging techniques. The aim of the present work was to standardize and validate an automatic synthesis module-based radiolabeling protocol for [Ga]Ga-PSMA-11, as well as to produce a radiopharmaceutical for PET imaging of PCa malignancies. Read More

View Article and Full-Text PDF

Accuracy of Prostate Magnetic Resonance Imaging: Reader Experience Matters.

Eur Urol Open Sci 2021 May 23;27:53-60. Epub 2021 Mar 23.

Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Background: Prostate magnetic resonance imaging (MRI) is increasingly used in the detection, image-guided biopsy, and active surveillance of prostate cancer. The accuracy of prostate MRI may differ based on factors including imaging technique, patient population, and reader experience.

Objective: To determine whether the accuracy of prostate MRI varies with reader experience. Read More

View Article and Full-Text PDF

Utility of 18F-Prostate-Specific Membrane Antigen 1007 in Imaging of Tumor Thrombus of Renal Cell Carcinoma.

Clin Nucl Med 2021 Apr 20. Epub 2021 Apr 20.

From the Department of Nuclear Medicine, Guangzhou Universal Medical Imaging Diagnostic Center, Guangzhou, China.

Abstract: A 64-year-old man was referred for 18F-prostate-specific membrane antigen 1007 PET/CT with a suspicion of recurrence and metastases of renal cell carcinoma after the resection of right renal cell carcinoma. The scan showed intense tracer concentration in the inferior vena cava and the right atrium, which was later proven on histopathologic examination as tumor thrombus of renal cell carcinoma. Adding on to previous studies with 18F-prostate-specific membrane antigen 1007 in the primary renal tumor, the case proved that the tumor thrombus of renal cell carcinoma could also show intense tracer concentration and further highlights its utility in renal cell carcinoma. Read More

View Article and Full-Text PDF

Current and future perspectives of digital microscopy with fluorescence confocal microscope for prostate tissue interpretation: a narrative review.

Transl Androl Urol 2021 Mar;10(3):1569-1580

Department of Urology, University of Modena and Reggio Emilia, Modena, Italy.

Fluorescence confocal microscopy (FCM) is an optical imaging technique providing digital microscopical images of fresh tissue in a real time fashion, without conventional processing. FCM has been widely applied in several fields of dermatology, including the detection of basal cell carcinoma and of cutaneous inflammatory diseases. The aim of the paper is to provide an overview of FCM applications in the field of prostate tissue interpretation and prostate cancer (PCa) detection. Read More

View Article and Full-Text PDF

Comparison of whole-body bone scintigraphy with axial skeleton magnetic resonance imaging in the skeletal evaluation of carcinoma prostate.

Indian J Urol 2021 Jan-Mar;37(1):72-78. Epub 2021 Jan 1.

Department of Urology, Amrita Institute of Medical Sciences, Kochi, Kerala, India.

Introduction: Whole-body bone scintigraphy (WBBS) is considered to be the standard of care in the initial skeletal evaluation of patients with carcinoma prostate. Magnetic resonance imaging (MRI) is a potential alternative technique for detecting bone metastasis. The objective of this study was to compare the diagnostic performance of WBBS with a single-photon emission computed tomography-computed tomography (SPECT-CT) correlation of the suspicious WBBS lesions to the axial skeleton (AS)-MRI in diagnosing bone metastasis in patients with carcinoma prostate. Read More

View Article and Full-Text PDF
January 2021

Correlation between Prostate Imaging Reporting and Data System Version 2, Prostate-Specific Antigen Levels, and Local Staging in Biopsy-Proven Carcinoma Prostate: A Retrospective Study.

Int J Appl Basic Med Res 2021 Jan-Mar;11(1):32-35. Epub 2021 Jan 26.

Department of Pathology, Government Medical College, Jammu, Jammu and Kashmir, India.

Background: Multi-parametric magnetic resonance imaging (mp-MRI) is a promising tool in the diagnosis of clinically significant prostate cancer. Morphologic assessment using T2-weighted (T2W) images and functional assessment with diffusion-weighted imaging is the cornerstone for the diagnosis of prostate cancer on mp-MRI.

Aim/objectives: The aim of this study is to evaluate the role of mp-MRI based prostate imaging reporting and data system version 2 (PI-RADS v2) for the assessment of prostate cancer and its correlation with serum prostate specific antigen (S. Read More

View Article and Full-Text PDF
January 2021

Biologically consistent dose accumulation using daily patient imaging.

Radiat Oncol 2021 Apr 6;16(1):65. Epub 2021 Apr 6.

Medical Physics in Radiation Oncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.

Background: This work addresses a basic inconsistency in the way dose is accumulated in radiotherapy when predicting the biological effect based on the linear quadratic model (LQM). To overcome this inconsistency, we introduce and evaluate the concept of the total biological dose, bEQD.

Methods: Daily computed tomography imaging of nine patients treated for prostate carcinoma with intensity-modulated radiotherapy was used to compute the delivered deformed dose on the basis of deformable image registration (DIR). Read More

View Article and Full-Text PDF

Feasibility study for fluorescence confocal microscopy (FCM) on diagnostic prostate biopsies.

Quant Imaging Med Surg 2021 Apr;11(4):1322-1332

Department of Urology, Klinikum Lippe GmbH, Detmold, Germany.

Background: Fluorescence confocal microscopy (FCM) is a novel micro-imaging technique providing optical sections of examined tissue. The method has been well established for the diagnosis of tumours in dermatological specimens. Preliminary results found good feasibility when this technique was used to examine prostate cancer (PCa) specimens. Read More

View Article and Full-Text PDF

Prospective Image Quality and Lesion Assessment in the Setting of MR-Guided Radiation Therapy of Prostate Cancer on an MR-Linac at 1.5 T: A Comparison to a Standard 3 T MRI.

Cancers (Basel) 2021 Mar 26;13(7). Epub 2021 Mar 26.

Department of Radiation Oncology, Eberhard-Karls University, 72076 Tuebingen, Germany.

The objective of this study is to conduct a qualitative and a quantitative image quality and lesion evaluation in patients undergoing MR-guided radiation therapy (MRgRT) for prostate cancer on a hybrid magnetic resonance imaging and linear accelerator system (MR-Linac or MRL) at 1.5 Tesla. This prospective study was approved by the institutional review board. Read More

View Article and Full-Text PDF

Nascent Prostate Cancer Heterogeneity Drives Evolution and Resistance to Intense Hormonal Therapy.

Eur Urol 2021 Mar 27. Epub 2021 Mar 27.

Laboratory of Genitourinary Cancer Pathogenesis, National Cancer Institute, Bethesda, MD, USA. Electronic address:

Background: Patients diagnosed with high risk localized prostate cancer have variable outcomes following surgery. Trials of intense neoadjuvant androgen deprivation therapy (NADT) have shown lower rates of recurrence among patients with minimal residual disease after treatment. The molecular features that distinguish exceptional responders from poor responders are not known. Read More

View Article and Full-Text PDF

Spurious Uptake on 68Ga-Prostate-Specific Membrane Antigen PET/CT Due to Ankylosing Spondylitis; A Rare Pitfall in Imaging of Biochemical Recurrence of Prostate Cancer.

Clin Nucl Med 2021 Mar 16. Epub 2021 Mar 16.

From the Department of Radiology, St James's Hospital, Dublin, Ireland.

Abstract: Bone is one of the most common sites of prostate cancer recurrence, and 68Ga-prostate-specific membrane antigen (PSMA) uptake by benign bone entities poses a diagnostic dilemma. We describe the case of a 60-year-old man with recurrence in a small presacral node on 68Ga-PSMA PET/CT. Of note, the images also demonstrated bilateral asymmetrical sacroiliac joint uptake. Read More

View Article and Full-Text PDF

Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT.

Clin Nucl Med 2021 Mar 16. Epub 2021 Mar 16.

From the Department of Radiology and Medical Imaging, University of Virginia, Charlottesville, VA Department of Radiology, North Eastern Indira Gandhi Regional Institute of Health and Medical Sciences, Mawdiangdiang, Shillong, Meghalaya, India Department of Radiology and Medical Imaging, University of Texas Health, San Antonio, TX.

Abstract: 18F-fluciclovine is a radiolabeled synthetic amino acid recently approved by the Food and Drug Administration for evaluating recurrent prostate cancer. Upregulated amino acid transporters in prostate cancer cells result in elevated radiotracer uptake in sites of tumor recurrence. However, 18F-fluciclovine is not specific for prostate cancer. Read More

View Article and Full-Text PDF

A Case of Renal Pelvic Cancer with a Complete Duplication of the Renal Pelvis and Ureter.

Case Rep Oncol 2021 Jan-Apr;14(1):202-206. Epub 2021 Mar 1.

Department of Urology, Yokosuka Kyosai Hospital, Yokosuka, Japan.

This paper describes a case of renal pelvic cancer with a complete duplication of the renal pelvis and ureter, which is substantially rare. A 76-year-old man was referred to the hospital because of gross hematuria for 2 years. A tumor was detected in the upper right kidney using enhanced computed tomography and magnetic resonance imaging scan, and the downstream ureter was suspected to open into the prostate. Read More

View Article and Full-Text PDF

Performance of fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography imaging for lymph node staging in bladder and upper tract urothelial carcinoma: a systematic review.

Arab J Urol 2020 Dec 10;19(1):59-66. Epub 2020 Dec 10.

Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

: To evaluate the current literature on the accuracy of fluoro-2-deoxy--glucose positron emission tomography-computed tomography (FDG PET-CT) for lymph node (LN) staging in urothelial carcinoma (UC), as robust evidence on the value of this technology in UC is still lacking. : The Medical Literature Analysis and Retrieval System Online (MEDLINE)/PubMed, Cochrane Library, and Scopus databases were searched for eligible studies. We included all original studies evaluating FDG PET-CT in bladder or upper tract UC. Read More

View Article and Full-Text PDF
December 2020

Molecular imaging and biochemical response assessment after a single cycle of [Ac]Ac-PSMA-617/[Lu]Lu-PSMA-617 tandem therapy in mCRPC patients who have progressed on [Lu]Lu-PSMA-617 monotherapy.

Theranostics 2021 16;11(9):4050-4060. Epub 2021 Feb 16.

Department of Nuclear Medicine, Saarland University - Medical Center, Homburg, Germany.

Despite the promising results of prostate-specific membrane antigen (PSMA)-targeted Lu radioligand therapy in metastatic castration-resistant prostate carcinoma (mCRPC), some patients do not respond and other patients with initially good response develop resistance to this treatment. In this study, we investigated molecular imaging and biochemical responses after a single cycle of [Ac]Ac-PSMA-617/[Lu]Lu-PSMA-617 tandem therapy in patients who had progressed on [Lu]Lu-PSMA-617 monotherapy. Seventeen patients with mCRPC were included in a retrospective, monocenter study. Read More

View Article and Full-Text PDF
February 2021

Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules.

J Med Chem 2021 Apr 17;64(7):4059-4070. Epub 2021 Mar 17.

Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, United States.

Fibroblast activation protein (FAP) has become a favored target for imaging and therapy of malignancy. We have synthesized and characterized two new (4-quinolinoyl)-glycyl-2-cyanopyrrolidine-based small molecules for imaging of FAP, and [In], using optical and single-photon computed tomography/CT, respectively. Binding of imaging agents to FAP was assessed in six human cancer cell lines of different cancer types: glioblastoma (U87), melanoma (SKMEL24), prostate (PC3), NSCLC (NCIH2228), colorectal carcinoma (HCT116), and lung squamous cell carcinoma (NCIH226). Read More

View Article and Full-Text PDF

Sarcomatoid carcinoma of the prostate with bladder invasion shortly after androgen deprivation: Two case reports.

World J Clin Cases 2021 Mar;9(7):1668-1675

Department of Urology, Cancer Hospital of Guangxi Medical University & Guangxi Cancer Research Institute, Nanning 530021, Guangxi Zhuang Autonomous Region, China.

Background: To summarize the imaging, morphological and biological characteristics of sarcomatoid carcinoma (SC) of the prostate with bladder invasion not long after castration.

Case Summary: Our two cases were initially diagnosed with adenocarcinoma of the prostate due to dysuria. However, prostate SC was diagnosed after transurethral resection of the prostate (TURP) and castration after only 5 and 10 mo, respectively. Read More

View Article and Full-Text PDF

F-PSMA-1007 PET/CT uptake in multiple angiolipomas caused by PSMA expression in capillaries: a case report.

Transl Androl Urol 2021 Feb;10(2):991-996

Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, China.

Prostate specific membrane antigen (PSMA) is a transmembrane glycoprotein that was originally cloned in the membrane of prostate gland epithelial cells. It has been confirmed to be highly expressed in prostate cancer cells, and in some non-prostatic tissues, including the brain and some benign lesions. PSMA-based imaging has been extensively used for the assessment of prostate carcinoma. Read More

View Article and Full-Text PDF
February 2021

Transcriptome Analysis of the Inhibitory Effect of Sennoside A on the Metastasis of Hepatocellular Carcinoma Cells.

Front Pharmacol 2020 12;11:566099. Epub 2021 Jan 12.

Shanghai University of Medicine & Health Sciences Affiliated Zhoupu Hospital, Shanghai, China.

Sennoside A (SA) is a bioactive component of with an activity of irritant laxative, which has been reported to possess therapeutic potential in various diseases or conditions including obesity, insulin resistance, liver steatosis, prostate cancer and pancreatic cancer progression. However, whether SA has therapeutic potential in hepatocellular carcinoma (HCC) treatment remains elusive. In this study, we treated two HCC cell lines, HepG2 and SMMC-7721 with SA and found that SA selectively inhibited the growth of HCC cells by proliferation assay. Read More

View Article and Full-Text PDF
January 2021

Results of a Randomized Phase II Trial of Intense Androgen Deprivation Therapy prior to Radical Prostatectomy in Men with High-Risk Localized Prostate Cancer.

J Urol 2021 Mar 8:101097JU0000000000001702. Epub 2021 Mar 8.

Dana-Farber Cancer Institute, Boston, Massachusetts.

Purpose: This multicenter randomized phase 2 trial investigates the impact of intense androgen deprivation on radical prostatectomy pathologic response and radiographic and tissue biomarkers in localized prostate cancer (NCT02903368).

Materials And Methods: Eligible patients had a Gleason score ≥4+3=7, PSA >20 ng/mL or T3 disease and lymph nodes <20 mm. In Part 1, patients were randomized 1:1 to apalutamide, abiraterone acetate, prednisone and leuprolide (AAPL) or abiraterone, prednisone, leuprolide (APL) for 6 cycles (1 cycle=28 days) followed by radical prostatectomy. Read More

View Article and Full-Text PDF

A choroid plexus metastasis of a prostatic adenocarcinoma mimicking a choroid plexus carcinoma: A case report.

Neurochirurgie 2021 Mar 3. Epub 2021 Mar 3.

Department of neurosurgery, Gui-de-Chauliac Hospital, Montpellier University medical centre, Montpellier, France.

A multicystic intraventricular tumour of the right ventricular atrium was incidentally diagnosed on follow-up imaging of a 61-year-old man with a history of prostatic adenocarcinoma. Surgical resection of the lesion was performed after a one-year radio-clinical follow-up due to progressive expansion of the lesion size and a rising prostate specific antigen blood-level. Morphological features with papillary pattern on pathological examination were compatible with malignant adenocarcinoma or choroid plexus carcinoma. Read More

View Article and Full-Text PDF

A Multi-Center, Multi-Vendor Study to Evaluate the Generalizability of a Radiomics Model for Classifying Prostate cancer: High Grade vs. Low Grade.

Diagnostics (Basel) 2021 Feb 22;11(2). Epub 2021 Feb 22.

Department of Radiology and Nuclear Medicine, Erasmus MC, 3015 GD Rotterdam, The Netherlands.

Radiomics applied in MRI has shown promising results in classifying prostate cancer lesions. However, many papers describe single-center studies without external validation. The issues of using radiomics models on unseen data have not yet been sufficiently addressed. Read More

View Article and Full-Text PDF
February 2021

[A Case of Prostatic Cancer that Had Bilateral Ureteral Metastases at Initial Diagnosis].

Hinyokika Kiyo 2021 Feb;67(2):67-71

The Department of Urology, Kansai Electric Power Hospital.

Ureteral metastases from prostate cancer are uncommon. We report a case of prostate cancer with bilateral ureteral metastases. A 76-year-old man visited our hospital because of serum prostate specific antigen (PSA) level of 40. Read More

View Article and Full-Text PDF
February 2021

Computerized tumor multinucleation index (MuNI) is prognostic in p16+ oropharyngeal carcinoma.

J Clin Invest 2021 04;131(8)

Department of Biomedical Engineering, Case Western Reserve University, Cleveland, Ohio, USA.

BACKGROUNDPatients with p16+ oropharyngeal squamous cell carcinoma (OPSCC) are potentially cured with definitive treatment. However, there are currently no reliable biomarkers of treatment failure for p16+ OPSCC. Pathologist-based visual assessment of tumor cell multinucleation (MN) has been shown to be independently prognostic of disease-free survival (DFS) in p16+ OPSCC. Read More

View Article and Full-Text PDF

Discovered cancers at postmortem donor examination: A starting point for quality improvement of donor assessment.

Transplant Rev (Orlando) 2021 Apr 20;35(2):100608. Epub 2021 Feb 20.

Department of Pathology and Diagnostics, University and Hospital Trust of Verona, Verona, Italy. Electronic address:

Background: clinical and imaging investigations allow a detailed assessment of an organ donor, but a quota of cancer still elude detection. Complete autopsy of donors is even less frequently performed, due to economic issues and increasing availability of high-quality imaging. The aim of this study is to gather evidence from the literature on donor malignancy discovered at autopsy following organ donation and to discuss the utility and limitations of autopsy practice in the field of transplantation. Read More

View Article and Full-Text PDF

Diagnostic Accuracy of Prebiopsy Ga-68 PSMA PET/CT in Detecting Primary Prostate Carcinomas with Prostate-Specific Antigen <50 ng/ml.

Indian J Nucl Med 2020 Oct-Dec;35(4):283-290. Epub 2020 Oct 21.

Department of Nuclear Medicine, MIOT International Hospital, Chennai, Tamil Nadu, India.

Background And Aim: Serum prostate-specific-antigen (PSA) guided systematic transrectal ultrasound (TRUS)-guided biopsies are known to have a low predictive value in detection of primary prostate carcinomas (PCa). Our aim was to evaluate the accuracy of gallium-68 (Ga-68) prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) for the detection of PCa with serum PSA <50 ng/ml.

Patients And Methods: We retrospective analyzed prebiopsy Ga-68 PSMA PET/CT's of all patients with suspected PCa from October 2019 to March 2020. Read More

View Article and Full-Text PDF
October 2020

Ga-PSMA-11 PET/CT in patients with occult biochemical recurrence of prostate carcinoma and negative F-Choline PET/CT. Preliminary assessment of its clinical use.

Actas Urol Esp 2021 Feb 23. Epub 2021 Feb 23.

Unidad de imagen molecular. CIMES-FGUMA, Málaga, España.

Objective: To assess the clinical usefulness of Ga-PSMA PET/CT studies in patients with occult biochemical recurrence of prostate carcinoma, with negative or inconclusive radiologic and 18F-Choline PET/CT imaging studies.

Material And Methods: Retrospective observational and diagnostic accuracy. The first 14 patients with a history of prostate carcinoma, treated with curative intent and presenting suspicion of biochemical recurrence with low PSA values (< 3 ng/ml) were selected. Read More

View Article and Full-Text PDF
February 2021